Medacta Group SA · SIX:MOVE
Medacta Group SA — FY2020 Earnings Presentation
23 slides from Medacta Group SA's earnings presentation, Mar 31, 2021
Slide 1: FY 2020 Financial Results
FY 2020 Financial Results 31 March 2021
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Medacta Group SA (“Medacta” and together with its subsidiaries, “we”, “us” or the “Group”). The information contained in the presentation does not purport to be comprehensive. Please refer to the Medacta 2020 Annual Report available on our website at
Slide 3: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer FY 2020 Financial Results
Slide 4: 2020 Highlights
2020 Highlights* * Alternative Performance Measures: This presentation contains certain financial measures of historical performance that are not defined or specified by IFRS, such as “constant currency", "EBITDA", "Adjusted EBITDA" or “CORE EBITDA”, "Free Cash Flow", “Adjusted Free Cash Flow”, “Net
Slide 5: FY 2020 Medacta's Achievements
FY 2020 Medacta’s Achievements Revenues equal to Euro 302.5 million, down only 2.1% on constant currency basis, significantly above market decline1, after growth of 7.6% on a constant currency basis in 2H driven by both pent-up demand and new customers acquired Adjusted EBITDA of Euro 88.1 milli
Slide 6: Redesigned Marketing and Education Offering
Redesigned Marketing and Education Offering Thanks to new marketing initiatives and digital education programs we were able to keep existing surgeons fully involved and engage new customers, leveraging national experts 2’900+ surgeons attended our online and digital education programs with significa
Slide 7: Strong R&D focus with 30+ new Products cleared
Strong R&D focus with 30+ new Products cleared #30+ new Products were cleared (CE or FDA) in 2020, including: In the Hip product line Completion of the renewal of primary implant offering and expansion of revision product range Launch of new solutions for 3D pre-operative planning and intra-op
Slide 8: NextAR Surgical Platform
NextAR™ Surgical Platform First surgeries were successfully performed in Australia and in the US, and the number of reference centers supporting future worldwide expansion is increasing The platform technology perfectly fits with sustainability of healthcare systems and particularly with US ambu
Slide 9: Corrado Farsetta, Chief Financial Officer
CORRADO FARSETTA Chief Financial Officer FY 2020 Financial Results
Slide 10: FY Revenue Bridge by Product Line
FY Revenue Bridge by Product Line1 (€m) -6.1% -4.1% 46.6% 14.6% (€m) 14.3; 28.9; 5% 9% 153.1; 106.2; 51% 35% 2 Hip Knee Extremities Spine Core business (Hip and Knee) was affected by postponement of elective procedures in 1H, partially compensated by an effective backlog recovery The Extremities
Slide 11: FY Revenue Bridge by Geographic Area
FY Revenue Bridge by Geographic Area1 (€m) -6.0% -1.0% 9.2% -29.2% (€m) 8.5; 3% 72.0; 24% 129.3; 43% 92.7; 30% Europe NA APAC ROW In Europe the most affected markets were France, Italy and Belgium; the “DACH” area recorded the smallest impact with Germany growing over the prior year In NA our in
Slide 12: FY 2020 P&L: Remarkable Profitability
FY 2020 P&L: Remarkable Profitability1 PROFIT & LOSS STATEMENT (€m) FY 2019 A FY 2020 A Revenues 310.6 302.5 Cost of Sales (86.9) (88.2) GROSS PROFIT 223.7 214.3 GROSS PROFIT MARGIN 72.0% 70.8% Research and Development expenses (7.6) (6.8) Sales and Marketing expenses (127.1) (110.1) General and Adm
Slide 13: FY 2020 Investments for Future Growth
FY 2020 Investments for Future Growth FY 2020 Investments €34.2m % of Revenues 11.3% (€m) Other Investments in instruments and in the Intangibles;3 development of new implants and 2.0; 6% surgical instruments to feed new R&D customers started in 2020 and sustain the Investments; 8.1; 24% growth
Slide 14: FY 2020 Positive Free Cash Flow Generation after Investments
FY 2020 Positive Free Cash Flow1 Generation after Investments for Future Growth ADJUSTED FREE CASH FLOW (€m) FY 2019 A FY 2020 A PROFIT FOR THE YEAR 11.9 37.1 P&L Adjustments: Income tax expenses 1.8 2.8 Depreciation and amortisation 33.7 37.0 Other P&L non-cash transactions 17.0 9.6 Movements in wo
Slide 15: Net Financial Debt: Low Leverage to Face New Investments
Net Financial Debt: Low Leverage1,2 to Face New Investments to Grow Leverage 1.15x 0.95x (€M) 105.6 83.3 Net Debt at 31 December 2019 Net Debt at 31 December 2020 Notes: 1. For a reconciliation of Alternative Performance Measures please refer to section headed “Alternative Performance Measures” of t
Slide 16: Francesco Siccardi, Chief Executive Officer
FRANCESCO SICCARDI Chief Executive Officer FY 2020 Financial Results
Slide 17: 2021 Outlook
2021 Outlook We will continue to monitor the evolution of the Covid-19 pandemic and impact on our reference market, while remaining committed to our future growth Despite uncertainty remaining in some geographies, we believe Medacta is well positioned to deliver growth as a result of our global
Slide 18: Q&A
Q&A FY 2020 Financial Results
Slide 19: Adedacta
Adedacta Adedacta International
Slide 20: Appendix
APPENDIX FY 2020 Financial Results
Slide 21: Consolidated Statement of Profit or Loss
Consolidated Statement of Profit or Loss 21
Slide 22: Consolidated Statement of Comprehensive Income
Consolidated Statement of Comprehensive Income 22
Slide 23: Consolidated Statement of Cash Flows
Consolidated Statement of Cash Flows 23